MNG824
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.573
- TNFA_SIGNALING_VIA_NFKB+0.495
- HYPOXIA+0.478
- ANDROGEN_RESPONSE+0.473
- ANGIOGENESIS+0.454
- KRAS_SIGNALING_UP+0.442
- TGF_BETA_SIGNALING+0.410
- ESTROGEN_RESPONSE_LATE+0.382
- ESTROGEN_RESPONSE_EARLY+0.372
- INFLAMMATORY_RESPONSE+0.367
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.330
- OXIDATIVE_PHOSPHORYLATION-0.329
- MYC_TARGETS_V2-0.309
- DNA_REPAIR-0.298
- NOTCH_SIGNALING-0.280
- WNT_BETA_CATENIN_SIGNALING-0.266
- BILE_ACID_METABOLISM-0.144
- PEROXISOME-0.048
- FATTY_ACID_METABOLISM+0.010
- ADIPOGENESIS+0.025
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_MKM0EEN1 | Diffuse intrinsic pontine glioma | — | 0.872 |
| 2 | SRR33346953 | — | — | 0.858 |
| 3 | MNG918 | — | — | 0.857 |
| 4 | EPT0578 | EPN | Posterior Fossa EPN | 0.847 |
| 5 | MDT-AP-2040 | Med | Medulloblastoma | 0.835 |
| 6 | MNG639 | — | — | 0.831 |
| 7 | SRR1313160 | — | E | 0.808 |
| 8 | SRR8392896 | — | cohortMD2 | 0.806 |
| 9 | MNG223 | — | — | 0.804 |
| 10 | MNG1172 | — | — | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.573 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.495 | Inavolisib | — uncovered |
| HYPOXIA | 0.478 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.473 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.454 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.442 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.382 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.372 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.367 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.364 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| COAGULATION | 0.345 | Binimetinib | — uncovered |
| APOPTOSIS | 0.342 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.335 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.334 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.311 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.295 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |